In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Too Many Drugs, Too Little Value in CV Conditions

Executive Summary

With the potential to treat multiple indications, a flood of cardiovascular drugs with purportedly novel mechanisms of action are expected to hit the market within 24 months. But because of the rapid progress in treating heart disease, what was novel years ago now appears mundane, diminishing the value of scientific breakthroughs that used to assure success.

You may also be interested in...

In Two Recent Trials, Devices Trump Rx

Results of two recent studies reported at this year's American Heart Association meeting favor devices over therapeutics in treating certain cardiovascular conditions. The PRESTO trial results were the equivalent of a dodged bullet for stent companies; it showed no benefit from the drug Tranilast, a result which leaves intact the supposition that drug-eluting stents are the best restenosis treatment. And another major trial found that implantable LVADs have superior results in treatment patients with chronic end-stage heart failure.

Thermo Fisher Scientific, Hillrom To Acquire Diagnostics Companies To Bolster Portfolios

Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.

Cosmetic And Personal Care Trademark Review 19 January, 2021

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts